T-2 toxin affects proliferation of three different neoplastic cell lines.
The antiproliferative effect of T-2 toxin (T-2) towards mouse melanoma B16 cells, human myelogenous leukemia K562 cells, and human cervix carcinoma, HeLa cells, was studied. For the first four days of T-2 presence B16 cell survival was decreased in dose dependent fashion. However, cell survival after eleven days T-2 action may be dual: some stimulation of cell growth that was direct function of the number of seeded cells per well was observed and cell survival (for the highest number of seeded cells) six times greater than control, was noticed at 20 nM T-2 toxin concentration. A smaller cell growth stimulation (cell survival more than 3 times higher than control) was observed with a lower cell number seeded per well. Nevertheless, by eleventh day concentrations of T-2 higher than 35 nM completely inhibited B16 cell proliferation. The same trend was noticed for T-2 action towards K562 cells. Treatment of HeLa cells with various T-2 concentrations led to a marked inhibition of cell survival that was more pronounced at the end of 44th or 72nd hour, than after the 20th hour of agent's action. ICs50 values obtained in the present work, suggest that B16 cells were the most sensitive to T-2 antiproliferative action, while HeLa cells were the most resistant. When PBMC were cultured with HeLa cells the antagonism against various T-2 concentrations was observed; cell survival determined after 44, or 72 hours of cells incubation, was less decreased compared to cultures treated with T-2, or with PBMC only. In addition, it was shown that T-2 and cis-DDP had an antagonist effect on HeLa cells survival.
Juranić
Z
Z
Institute of Oncology and Radiology of Serbia, Belgrade, Yugoslavia.
Stojiljković
M P
MP
Bocarov-Stancić
A
A
Kilibarda
V
V
Milovanović
S R
SR
Juranić
I
I
Bijelogrlić
S
S
Vuletić
N
N
Radulović
S
S
D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D006131:Growth Inhibitors / Q000494:pharmacology*; D006367:HeLa Cells / Q000187:drug effects*; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008546:Melanoma, Experimental / Q000473:pathology*; D013605:T-2 Toxin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D006131:Growth Inhibitors; D013605:T-2 Toxin